Ecologic Study of Meningococcal B Vaccine andNeisseria gonorrhoeaeInfection, Norway

Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway.

A new meningococcal B vaccine

Neisseria meningitidis is an important cause of invasive bacterial infection in children worldwide, and is a rare example of a bacterium that has evolved to become an obligate human commensal which commonly colonizes the oropharyngeal mucosa. Carriage is age-dependent and appears to be very common in young adults. The relationships between carriage and invasive disease are not completely unders...

Understanding the Category B Recommendation for Serogroup B Meningococcal Vaccine.

Published recommendations of the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention, which carry the approval of the Secretary of Health and Human Services, provide guidance on how licensed vaccines should be used. Professional organizations such as the American Academy of Family Physicians and the American Academy of Pediatrics (AAP) also deve...

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

The effectiveness of a new group B strain-specific meningococcal vaccine referred to as "MeNZB," developed by Chiron Vaccines (Siena, Italy) in collaboration with the Norwegian Institute of Public Health, was assessed in a prospective observational study following a nationwide vaccination program in New Zealand. The vaccination program began in July 2004, and the study uses data from January 20...

Enter B and W: two new meningococcal vaccine programmes launched

In 2015, the UK became the first country in the world to have a comprehensive routine meningococcal vaccine programme targeting all of the main capsular groups of N. meningitidis. 1 An infant vaccine programme against meningococcal capsular group B Neisseria meningitidis (MenB) was launched from 1st September with an aim to reduce endemic MenB disease in early childhood. On 1st August 2015, an ...